AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00981643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation instruction and practice
Description: Meditation techniques introduced and practiced, in a group setting, once weekly for 8 weeks
Study NCT03351569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Description: Intravenous drip.
Study NCT03351569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous immunoglobulin
Description: Intravenous drip.
Study NCT01664858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3T CMR
Description: 3Tesla Cardiac Magnetic Resonance Imaging
Study NCT01436799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: anaesthesia was induced with the effect-site concentration of propofol 5.0 μg ml-1 mainly.
Study NCT01436799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: anaesthesia was maintained by desflurane 4-7vol%
Study NCT01436799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alfentanil
Description: administration of alfentanil 10 μg kg-1 for anesthetic induction
Study NCT01436799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alfentanil
Description: administration of alfentanil 10 μg kg-1 for anesthetic induction
Study NCT01436799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: administration of rocuronium 0.6 mg kg-1 for anesthetic induction
Study NCT01436799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: administration of rocuronium 0.6 mg kg-1 for anesthetic induction
Study NCT01907126 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition Program (NP)
Description: Nutrition Program (NP) participants will receive the same number, format, and schedule of group and individual 60-minute sessions, which will focus on low-cost strategies for improving nutrition.
Study NCT01907126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women's Prison CoOp (WPC)
Description: Weekly as 60-minute sessions, 3 group and two individual sessions during incarceration as close to prison discharge as possible. Session 1 focuses on understanding and reviewing HIV risks, including interpersonal violence. Session 2 addresses gender, power, violence, and affect management to counter the emotional effects of violence. Session 3 addresses IV-specific sexual safety skills, including affect management skills. Session 4 helps women begin to develop a personalized safety plan, which may include increasing social support and access to resources. Session 5 helps her finalize and practice the plan, and Session 6 problem-solves any difficulties that have arisen in executing the plan.
Study NCT03693573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
Study NCT03693573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion at 15 mg/kg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
Study NCT01881113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-170 0.24%
Description: 1 drop in each eye at 2 separate times during a 14 day period
Study NCT01881113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AC-170 0%
Description: 1 drop in each eye at 2 separate times during a 14 day period
Study NCT05154812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yang Yin Fu Zheng Jie Du therapy
Description: Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
Study NCT05154812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Routine medical care
Description: Routine medical care
Study NCT06458842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study NCT06458842 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01155024 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Traditional fabricated prosthetic socket
Description: A prosthetic socket constructed utilizing traditional techniques. This intervention is a control and the basis for comparison.
Study NCT01155024 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Direct manufactured (DM) prosthetic socket
Description: A prosthetic socket constructed from direct manufacturing technique. The socket will be tested under both diagnostic and definitive environments. Diagnostic testing will span several hours (4-6 hours) and definitive testing will span several months (3-6 months)
Study NCT05555563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MTAD irrigation
Description: Final irrigation protocol was performed using 5 ml MTAD (n=50).
Study NCT00861198 — intervention group
Intervention type: OTHER
Intervention: ERCP as per medical indication
Description: ERCP as per medical indication
Study NCT01345435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring group
Description: The Telemonitoring group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should visit the site once per every 2 months (8 weeks), and measure their blood glucose using a provided blood glucose monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management
Study NCT01345435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring & Telemedicine
Description: The Telemonitoring \& Telemedicine group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should measure their blood glucose using a provided blood glucose monitor twice a day during the study period. After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management. A remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring PC and then issue electronic prescriptions.
Study NCT01345435 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SMBG
Description: The subjects who are assigned in the control group will be provided blood glucose Monitor. The subjects who are assigned in the control group should perform the same blood glucose measurement same as the test group during the study, and measured results should be recorded in a diary of self blood glucose measurement. In addition, the subjects should visit the site once per every two months (8 weeks).
Study NCT04619992 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Currently marketed Hydrophillic Intermittent Catheter
Description: Currently marketed Hollister standard with tip hydrophilic intermittent catheter
Study NCT04619992 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Test Hydrophilic Intermittent Catheter
Description: Hollister standard with tip hydrophilic intermittent catheter with design enhancements
Study NCT00739986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semapimod
Description: semapimod 60 mg IV x 1 day, placebo x 2 days
Study NCT00739986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semapimod
Description: Semapimod 60 mg IV x 3 days
Study NCT00739986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo IV x 3 days
Study NCT00967044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Starting dose of 10 mg by mouth per day, self-administered (by patients), three times per week
Study NCT00967044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Starting dose of 5 mg every day by mouth with 1 cup (8 ounces) of water, in morning after eating a low-fat meal.
Study NCT02440113 — intervention group
Intervention type: DEVICE
Intervention: Nellix
Description: Nellix Implantation
Study NCT01350843 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Orange Juice
Description: 250ml of orange juice or a sugars matched orange drink daily
Study NCT01350843 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange Juice
Description: 250ml of orange juice or a sugars matched orange drink daily
Study NCT04276844 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography using the two-dimensional (2D) mode
Description: Diaphragmatic amplitude assessed by ultrasonography during quiet breathing and after sniff test, before the surgery and at day 7 post-surgery in all patients.
Study NCT04276844 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory Functional Explorations
Description: Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV) and total lung capacity (TLC) measured at day 7
Study NCT00468728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAR-101/OPT-80
Description: capsules
Study NCT00468728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Capsules
Study NCT02244918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Participant has choice of from over-the-counter nicotine patch, nicotine gum or lozenge.
Study NCT02244918 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Study NCT02244918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Counseling
Study NCT03386565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride solution
Description: intraoperative IV infusion
Study NCT03386565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: intraoperative IV infusion
Study NCT02754908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: musical training
Description: The subjects in the experimental group will receive weekly 45-minute lessons on musical training for one year (52 weeks), conducted by the Music Children Foundation.
Study NCT02754908 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: tutoring classes
Description: They will be invited to attend free, weekly 45-minute tutoring classes organised by the community for one year (52 weeks).
Study NCT03178526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovastatin gel
Description: Lovastatin gel1.2% topical gel was put into teh periodontal pocket using an insulin syringe
Study NCT03178526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo gel
Study NCT02893202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Horseback riding
Description: An 8-week equine-assisted program designed to especially for veterans. The curriculum consists of eight 90-minute sessions designed to teach basic horse care and riding skills along with communication skills.
Study NCT01664858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SPECT
Description: SPECT: Single Photon Emission Computed Tomography
Study NCT00997984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended-release guanfacine hydrochloride (SPD503)
Description: dosed in AM
Study NCT00997984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: dosed in the AM or PM
Study NCT00997984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended-release guanfacine hydrochloride
Description: Dosed in the PM
Study NCT02775266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alpha lipoic acid
Description: Scaling and root planing will be done at baseline and systemic antioxidant Alpha lipoic acid 1800mg/day in 3 divided doses for a period of 3 months.
Study NCT02775266 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Root planing
Description: Scaling and root planing will be done at baseline.
Study NCT02775266 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and Root planing
Description: Scaling and root planing will be done at baseline.
Study NCT01361217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine, Lovastatin, Omeprazole, caffeine, midazolam, dextromethorphan
Description: 1x20mg oral fluoxetine capsules by mouth daily on Study Day 5, then 3x20mg fluoxetine capsules by mouth daily on Study Days 6 through 18.~On study day 1 and study day 18, 100mg caffeine, 2mg midazolam, 30mg dextromethorphan and 20mg omeprazole (enteric coated formulation) orally with 250mL of water.~On study day 3 and study day 20 20mg of lovastatin with 250mL of water.
Study NCT04466384 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BIS
Description: Subjects will be sequentially assigned to the propofol or propofol and remifentanil group. The purpose is to capture the BIS value in association with these anesthetics.
Study NCT04442568 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERAS
Description: early mobilisation, early oral intake, early discharge
Study NCT01664858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CT calcium score
Description: CT calcium score
Study NCT01664858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CT coronary angiography
Description: CT coronary angiography
Study NCT00362882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00362882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00362882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: correlative study
Study NCT00362882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: correlative study
Study NCT00362882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: correlative study
Study NCT00362882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: correlative study
Study NCT04256473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mutant pro-urokinase
Description: Intravenous administration
Study NCT04256473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Intravenous administration
Study NCT01600404 — intervention group
Intervention type: DRUG
Intervention: antimuscarinic treatment
Study NCT01518387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate (BAY77-1931)
Study NCT01669746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cultured mixed population of dermal cells
Description: A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
Study NCT03491033 — intervention group
Intervention type: DRUG
Intervention: chemotherapy
Description: All of the patients in this study underwent NAC regimens consisting of taxane and platinum combination chemotherapy. After NAC, all of the patients underwent interval debulking surgery. Subsequently, additional cycles of chemotherapy were administered after IDS to complete a total of 6 cycles at the discretion of the treating physician.
Study NCT02824523 — intervention group
Intervention type: DRUG
Intervention: aspirin
Study NCT03924544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decorin
Description: Antifibrotic agent
Study NCT03924544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin c
Description: Antifibrotic agent
Study NCT03175731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors
Description: Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
Study NCT03175731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
Study NCT04476381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Insertion of a Optimed 40mm x 0.30 single use, sterile acupuncture needle into a active trigger point in the infraspinatus muscle
Study NCT02138812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1161909
Description: Given orally, with a starting dose of 0.75 mg twice daily from C1D1 onwards in a 2 days on/5 days off dosing schedule as single agent treatment in Cycle 1 (14 days), and from C2D8 onwards in a 2 days on/5 days off dosing schedule in 28-day cycles. For single-dose PK cohort: a single oral dose on C1D1
Study NCT02138812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 75 mg/m\^2 (initial dose escalation) or 90 mg/m\^2 (second dose escalation), weekly intravenously (IV) infusion on D1, D8, and D15 of the 28-day cycles from C2D1
Study NCT00003869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboxyamidotriazole
Description: Given PO
Study NCT00003869 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT00003869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00003869 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00003869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00003869 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00751712 — intervention group
Intervention type: DEVICE
Intervention: Cerebral oximeter sensor
Description: The INVOS Cerebral Oximeter utilizes two electrodes to monitor cerebral oxygenation. The recommended placement of these electrodes is on the forehead to monitor the frontal cortex. In this study, one electrode will be placed in the normal position on the forehead, and the other will be placed at the base of the skull. The stickers will be placed on the patient at the beginning of surgery and removed at the end. The maximum amount of time that they will be on the patient's skin is approximately six hours. Application of the stickers and the data they provide will not alter the provider's treatment plan. This procedure will be used for all enrolled patients, whether they are enrolled in Part I or Part II.
Study NCT03484429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation
Description: Up to 60 days of peripheral nerve stimulation
Study NCT03484429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: Medications, physical therapy, or other pain treatments
Study NCT03484429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Medications, physical therapy, or other pain treatments
Study NCT04138511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECOFISIO
Description: The ECOFISIO application is focused on sports pathologies and contains relevant written and digital information about ultrasound imaging and managing as well as diagnosis of sport injuries.
Study NCT04078204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylphthalide Soft Capsules
Description: The experimental group will receive the Butylphthalide Soft Capsules during the 24-month intervention period. After the 24-month intervention,The experimental group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
Study NCT04078204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo Soft Capsules
Description: The placebo group will receive the Placebo Soft Capsules during the 24-month intervention period. After the 24-month intervention,The placebo group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
Study NCT02073812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPX7009 and RPX2014
Description: The study is designed to enroll approximately 25 healthy subjects. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Carbavance (RPX7009/RPX2014)
Study NCT00002548 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: 3 million units/m2 SQ Monday-Wednesday~-Friday (3 times a week)
Study NCT00002548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: 20 mg/m2 I.V. day 1 q 35 days